New HSP90 selective inhibitors as therapeutic agents for prostate and bladder cancer.

被引：2
|
作者：
Liu, Weiya
Jensen, Derek
Lee, Eugene
Gills, Jessie
Holzbeierlein, Jeffrey M.
机构：
[1] Univ Kansas Med Ctr Dept Urol, Kansas City, KS USA
[2] Univ Kansas Med Ctr, Kansas City, KS USA
[3] Louisiana State Univ, Baton Rouge, LA, Lithuania
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.285
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
285
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A new HSP90 inhibitor as therapeutic agent for bladder cancer.
    Liu, Weiya
    Lee, Eugene K.
    Pirani, Karim
    Blagg, Brian S. J.
    Holzbeierlein, Jeffrey M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [2] Hsp90 as a therapeutic target in prostate cancer
    Solit, DB
    Scher, HI
    Rosen, N
    SEMINARS IN ONCOLOGY, 2003, 30 (05) : 709 - 716
  • [3] Hsp90 inhibitors as novel cancer chemotherapeutic agents
    Neckers, L
    TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) : S55 - S61
  • [4] Hsp90 inhibitors as promising agents for radiotherapy
    Alexander E. Kabakov
    Vladimir A. Kudryavtsev
    Vladimir L. Gabai
    Journal of Molecular Medicine, 2010, 88 : 241 - 247
  • [5] Hsp90 inhibitors as promising agents for radiotherapy
    Kabakov, Alexander E.
    Kudryavtsev, Vladimir A.
    Gabai, Vladimir L.
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2010, 88 (03): : 241 - 247
  • [6] Maximizing the Therapeutic Potential of HSP90 Inhibitors
    Butler, Lisa M.
    Ferraldeschi, Roberta
    Armstrong, Heather K.
    Centenera, Margaret M.
    Workman, Paul
    MOLECULAR CANCER RESEARCH, 2015, 13 (11) : 1445 - 1451
  • [7] 4,5-diarylisoxazole HSP90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer
    Brough, Paul A.
    Aherne, Wynne
    Barril, Xavier
    Borgognoni, Jenifer
    Boxall, Kathy
    Cansfield, Julie E.
    Cheung, Kwai-Miny J.
    Collins, Ian
    Davies, Nicholas G. M.
    Drysdale, Martin J.
    Dymock, Brian
    Eccles, Suzanne A.
    Finch, Harry
    Fink, Alexandra
    Hayes, Angela
    Howes, Robert
    Hubbard, Roderick E.
    James, Karen
    Jordan, Allan M.
    Lockie, Andrea
    Martins, Vanessa
    Massey, Andrew
    Matthews, Thomas P.
    McDonald, Edward
    Northfield, Christopher J.
    Pearl, Laurence H.
    Prodromou, Chrisostomos
    Ray, Stuart
    Raynaud, Florence I.
    Roughley, Stephen D.
    Sharp, Swee Y.
    Surgenor, Allan
    Walmsley, D. Lee
    Webb, Paul
    Wood, Mike
    Workman, Paul
    Wrightt, Lisa
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (02) : 196 - 218
  • [8] CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for HSP90 inhibition in prostate cancer.
    Lamoureux, F.
    Yin, M.
    Zoubeidi, A.
    Gleave, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Recent Advances in Hsp90 Inhibitors as Antitumor Agents
    Messaoudi, S.
    Peyrat, J. F.
    Brion, J. D.
    Alami, M.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2008, 8 (07) : 761 - 782
  • [10] Combination of inhibitors of Hsp90 chaperone activity and inhibitors of Hsp induction for better targeting human prostate cancer
    Kabakov, Alexander
    Kudryavtsev, Vladimir
    Demidkina, Anna
    Mosina, Vera
    BJU INTERNATIONAL, 2015, 116 : 39 - 39
12345